Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations

Metabolomics

Volumn 8, Issue 6, 2012, Pages 1102-1113

  Zivkovic, Angela M ^a   Yang, Jun ^a   Georgi, Katrin ^a   Hegedus, Christine ^a   Nording, Malin L ^a   O'Sullivan, Aifric ^a   German, J Bruce ^a   Hogg, Ronald J ^b   Weiss, Robert H ^a   Bay, Curt ^c   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c A T STILL UNIVERSITY   (United States)

Author keywords

3 fatty acid; DHA; Eicosanoids; EPA; Inflammation; Kidney function; Metabolomics; Oxylipins; Signaling lipids

Indexed keywords

10 (11)EPOXYDOCOSAPENTAENOIC ACID; 12 HYDROXYEICOSAPENTAENOIC ACID; 17,18 DIHYDROXYEICOSATRIENOIC ACID; CORN OIL; DOCOSAHEXAENOIC ACID; EPOXIDE; FATTY ACID; FISH OIL; HYDROXYIECOSATETRAENOIC ACID; HYDROXYOCTADECADIENOIC ACID; ICOSAPENTAENOIC ACID; ICOSATRIENOIC ACID; LEUKOTRIENE B4; LIPOXYGENASE; OXYLIPIN; PROSTAGLANDIN; PROSTAGLANDIN D3; PROSTAGLANDIN SYNTHASE; RESOLVIN E1; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; FATTY ACID BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DYSFUNCTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; METABOLOMICS; OUTCOME ASSESSMENT; PROTEINURIA; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; TREATMENT DURATION;

ANIMALIA; ZEA MAYS;

EID: 84868383463     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-012-0417-5     Document Type: Article

References (52)

1. Alexopoulos, E., Stangou, M., Pantzaki, A., Kirmizis, D., & Memmos, D. (2004). Treatment of severe IgA nephropathy with omega-3 fatty acids: The effect of a "very low dose" regimen. Renal Failure, 26(4), 453-459.
2. Appel, G. B., & Waldman, M. (2006). The IgA nephropathy treatment dilemma. Kidney International, 69(11), 1939-1944.
3. Baratelli, F., Krysan, K., Heuze-Vourc'h, N., Zhu, L., Escuadro, B., Sharma, S., et al. (2005a). PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells. Journal of Leukocyte Biology, 78(2), 555-564. doi: 10. 1189/jlb. 1004569.
4. Baratelli, F., Lin, Y., Zhu, L., Yang, S. C., Heuze-Vourc'h, N., Zeng, G., et al. (2005b). Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+T cells. Journal of Immunology, 175(3), 1483-1490.
5. Baxter, G. M. (1995). Alterations of endothelium-dependent digital vascular responses in horses given low-dose endotoxin. Veterinary Surgery, 24(2), 87-96.
6. Bennett, W. M., Walker, R. G., & Kincaid-Smith, P. (1989). Treatment of IgA nephropathy with eicosapentanoic acid (EPA): A two-year prospective trial. Clinical Nephrology, 31(3), 128-131.
7. Branten, A. J., Klasen, I. S., & Wetzels, J. F. (2002). Short-term effects of fish oil treatment on urinary excretion of high- and low-molecular weight proteins in patients with IgA nephropathy. Clinical Nephrology, 58(4), 267-274.
8. Catella-Lawson, F. (2001). Vascular biology of thrombosis: Platelet-vessel wall interactions and aspirin effects. Neurology, 57(5 Suppl 2), S5-S7.
9. Chang, J. H., Kim, D. K., Kim, H. W., Park, S. Y., Yoo, T. H., Kim, B. S., et al. (2009). Changing prevalence of glomerular diseases in Korean adults: A review of 20 years of experience. Nephrology, Dialysis, Transplantation, 24(8), 2406-2410. doi: 10. 1093/ndt/gfp091.
10. Cheng, I. K., Chan, P. C., & Chan, M. K. (1990). The effect of fish-oil dietary supplement on the progression of mesangial IgA glomerulonephritis. Nephrology, Dialysis, Transplantation, 5(4), 241-246.
11. Clevers, H. (2006). Colon cancer-understanding how NSAIDs work. New England Journal of Medicine, 354(7), 761-763. doi: 10. 1056/NEJMcibr055457.
12. Donadio, J. V., & Grande, J. P. (2004). The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. Seminars in Nephrology, 24(3), 225-243.
13. Donadio, J. V., Bergstralh, E. J., Offord, K. P., Holley, K. E., & Spencer, D. C. (1994a). Clinical and histopathologic associations with impaired renal function in IgA nephropathy. Mayo Nephrology Collaborative Group. Clinical Nephrology, 41(2), 65-71.
14. Donadio, J. V, Jr, Bergstralh, E. J., Offord, K. P., Spencer, D. C., & Holley, K. E. (1994b). A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. New England Journal of Medicine, 331(18), 1194-1199.
15. Donadio, J. V, Jr, Grande, J. P., Bergstralh, E. J., Dart, R. A., Larson, T. S., & Spencer, D. C. (1999). The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. Journal of the American Society of Nephrology, 10(8), 1772-1777.
16. Donadio, J. V, Jr, Larson, T. S., Bergstralh, E. J., & Grande, J. P. (2001). A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. Journal of the American Society of Nephrology, 12(4), 791-799.
17. Funk, C. D. (2001). Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science, 294(5548), 1871-1875.
18. Harmon, S. D., Fang, X., Kaduce, T. L., Hu, S., Raj Gopal, V., Falck, J. R., et al. (2006). Oxygenation of [omega]-3 fatty acids by human cytochrome P450 4F3B: Effect on 20-hydroxyeicosatetraenoic acid production. Prostaglandins Leukotrienes and Essential Fatty Acids, 75(3), 169-177.
19. Hogg, R. J. (1995). A randomized, placebo-controlled, multicenter trial evaluating alternate-day prednisone and fish oil supplements in young patients with immunoglobulin A nephropathy. Scientific Planning Committee of the IgA Nephropathy Study. American Journal of Kidney Diseases, 26(5), 792-796.
20. Hogg, R. J., Lee, J., Nardelli, N., Julian, B. A., Cattran, D., Waldo, B., et al. (2006). Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: Report from the Southwest Pediatric Nephrology Study Group. Clinical Journal of the American Society of Nephrology, 1(3), 467-474. doi: 10. 2215/CJN. 01020905.
21. Holman, R. T., Johnson, S. B., Bibus, D., Spencer, D. C., & Donadio, J. V, Jr. (1994). Essential fatty acid deficiency profiles in idiopathic immunoglobulin A nephropathy. American Journal of Kidney Diseases, 23(5), 648-654.
22. Imig, J. D., Zhao, X., Zaharis, C. Z., Olearczyk, J. J., Pollock, D. M., Newman, J. W., et al. (2005). An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension, 46(4), 975-981. doi: 10. 1161/01. HYP. 0000176237. 74820. 75.
23. Jira, W., Spiteller, G., & Richter, A. (1997). Increased levels of lipid oxidation products in low density lipoproteins of patients suffering from rheumatoid arthritis. Chemistry and Physics of Lipids, 87(1), 81-89.
24. Jira, W., Spiteller, G., Carson, W., & Schramm, A. (1998). Strong increase in hydroxy fatty acids derived from linoleic acid in human low density lipoproteins of atherosclerotic patients. Chemistry and Physics of Lipids, 91(1), 1-11.
25. Larsen, B. T., Miura, H., Hatoum, O. A., Campbell, W. B., Hammock, B. D., Zeldin, D. C., et al. (2006). Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: Implications for soluble epoxide hydrolase inhibition. American Journal of Physiology-Heart and Circulatory Physiology, 290(2), H491-H499. doi: 10. 1152/ajpheart. 00927. 2005.
26. Li, H., Ruan, X. Z., Powis, S. H., Fernando, R., Mon, W. Y., Wheeler, D. C., et al. (2005). EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: Evidence for a PPAR-[gamma]-dependent mechanism. Kidney International, 67(3), 867-874.
27. Libetta, C., Rampino, T., Palumbo, G., Esposito, C., & Dal Canton, A. (1997). Circulating serum lectins of patients with IgA nephropathy stimulate IL-6 release from mesangial cells. Journal of the American Society of Nephrology, 8(2), 208-213.
28. Menegatti, E., Roccatello, D., Fadden, K., Piccoli, G., De Rosa, G., Sena, L. M., et al. (1999). Gene expression of 5-lipoxygenase and LTA4 hydrolase in renal tissue of nephrotic syndrome patients. Clinical and Experimental Immunology, 116(2), 347-353.
29. Mestecky, J., Hashim, O. H., & Tomana, M. (1995). Alterations in the IgA carbohydrate chains influence the cellular distribution of IgA1. Contributions to Nephrology, 111, 66-71. discussion 71-62.
30. Myllymaki, J., Syrjanen, J., Helin, H., Pasternack, A., Kattainen, A., & Mustonen, J. (2006). Vascular diseases and their risk factors in IgA nephropathy. Nephrology, Dialysis, Transplantation, 21(7), 1876-1882. doi: 10. 1093/ndt/gfl062.
31. Negishi, M., Shimizu, H., Okada, S., Kuwabara, A., Okajima, F., & Mori, M. (2004). 9HODE stimulates cell proliferation and extracellular matrix synthesis in human mesangial cells via PPARgamma. Experimental biology and medicine (Maywood), 229(10), 1053-1060.
32. Newman, J. W., Kaysen, G. A., Hammock, B. D., & Shearer, G. C. (2007). Proteinuria increases oxylipid concentrations in VLDL and HDL but not LDL particles in the rat. Journal of Lipid Research, 48(8), 1792-1800. doi: 10. 1194/jlr. M700146-JLR200.
33. Obinata, H., Hattori, T., Nakane, S., Tatei, K., & Izumi, T. (2005). Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A. Journal of Biological Chemistry, 280(49), 40676-40683. doi: 10. 1074/jbc. M507787200.
34. Parinyasiri, U., Ong-Ajyooth, L., Parichatikanond, P., Ong-Ajyooth, S., Liammongkolkul, S., & Kanyog, S. (2004). Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy. Journal of the Medical Association of Thailand, 87(2), 143-149.
35. Peeraully, M. R., Sievert, H., Bullo, M., Wang, B., & Trayhurn, P. (2006). Prostaglandin D2 and J2-series (PGJ2, Delta12-PGJ2) prostaglandins stimulate IL-6 and MCP-1, but inhibit leptin, expression and secretion by 3T3-L1 adipocytes. Pflugers Archiv European Journal of Physiology, 453(2), 177-187. doi: 10. 1007/s00424-006-0118-x.
36. Pettersson, E. E., Rekola, S., Berglund, L., Sundqvist, K. G., Angelin, B., Diczfalusy, U., et al. (1994). Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: A prospective, double-blind, randomized study. Clinical Nephrology, 41(4), 183-190.
37. Rifai, A., Sakai, H., & Yagame, M. (1993). Expression of 5-lipoxygenase and 5-lipoxygenase activation protein in glomerulonephritis. Kidney International Supplements, 39, S95-S99.
38. Roccatello, D., Picciotto, G., Torchio, M., Ropolo, R., Ferro, M., Franceschini, R., et al. (1993). Removal systems of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients. The role of asialoglycoprotein receptors. Laboratory Investigation, 69(6), 714-723.
39. Serhan, C. N., & Chiang, N. (2004). Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: Entree for resoleomics. Rheumatic Diseases Clinics of North America, 30(1), 69-95. doi: 10. 1016/S0889-857X(03)00117-0.
40. Sulikowska, B., Manitius, J., Nieweglowski, T., Szydlowska-lysiak, W., & Rutkowski, B. (2002). The effect of therapy with small doses of mega-3 polyunsaturated fatty acid on renal reserve and metabolic disturbances in patients with primary IGA glomerulopathy. Polskie Archiwum Medycyny Wewnetrznej, 108(2), 753-760.
41. Sulikowska, B., Nieweglowski, T., Manitius, J., Lysiak-Szydlowska, W., & Rutkowski, B. (2004). Effect of 12-month therapy with omega-3 polyunsaturated acids on glomerular filtration response to dopamine in IgA nephropathy. American Journal of Nephrology, 24(5), 474-482.
42. Swaminathan, S., Leung, N., Lager, D. J., Melton, L. J, 3rd, Bergstralh, E. J., Rohlinger, A., et al. (2006). Changing incidence of glomerular disease in Olmsted County, Minnesota: A 30-year renal biopsy study. Clinical Journal of the American Society of Nephrology, 1(3), 483-487. doi: 10. 2215/CJN. 00710805.
43. Syrjanen, J., Huang, X. H., Mustonen, J., Koivula, T., Lehtimaki, T., & Pasternack, A. (2000). Angiotensin-converting enzyme insertion/deletion polymorphism and prognosis of IgA nephropathy. Nephron, 86(2), 115-121.
44. Taccone-Gallucci, M., Manca-di-Villahermosa, S., Battistini, L., Stuffler, R. G., Tedesco, M., & Maccarrone, M. (2006). N-3 PUFAs reduce oxidative stress in ESRD patients on maintenance HD by inhibiting 5-lipoxygenase activity. Kidney International, 69(8), 1450-1454.
45. Tager, A. M., Bromley, S. K., Medoff, B. D., Islam, S. A., Bercury, S. D., Friedrich, E. B., et al. (2003). Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nature Immunology, 4(10), 982-990. doi: 10. 1038/ni970.
46. Viswanathan, S., Hammock, B. D., Newman, J. W., Meerarani, P., Toborek, M., & Hennig, B. (2003). Involvement of CYP 2C9 in mediating the proinflammatory effects of linoleic acid in vascular endothelial cells. Journal of the American College of Nutrition, 22(6), 502-510.
47. Wang, L., Gill, R., Pedersen, T. L., Higgins, L. J., Newman, J. W., & Rutledge, J. C. (2009). Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. Journal of Lipid Research, 50(2), 204-213. doi: 10. 1194/jlr. M700505-JLR200.
48. Shearer, G. C., Harris, W. S., Pedersen, T. L., & Newman, J. W. (2009). Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. Journal of Lipid Research, 51(8), 2074-2081. doi: 10. 1194/M900193-JLR200.
49. Yang, J., Schmelzer, K., Georgi, K., & Hammock, B. D. (2009). Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Analytical Chemistry, 81(19), 8085-8093. doi: 10. 1021/ac901282n.
50. Ye, D., Zhang, D., Oltman, C., Dellsperger, K., Lee, H. C., & VanRollins, M. (2002). Cytochrome p-450 epoxygenase metabolites of docosahexaenoate potently dilate coronary arterioles by activating large-conductance calcium-activated potassium channels. Journal of Pharmacology and Experimental Therapeutics, 303(2), 768-776.
51. Zhao, X., Yamamoto, T., Newman, J. W., Kim, I. H., Watanabe, T., Hammock, B. D., et al. (2004). Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. Journal of the American Society of Nephrology, 15(5), 1244-1253.
52. Zivkovic, A. M., Wiest, M. M., Nguyen, U. T., Davis, R., Watkins, S. M., & German, J. B. (2009). Effects of sample handling and storage on quantitative lipid analysis in human serum. Metabolomics, 5(4), 507-516. doi: 10. 1007/s11306-009-0174-2.